This white paper presents expert perspectives on how artificial intelligence will transform pharmacovigilance and drug safety by 2026. It examines applications such as signal detection, case processing automation, literature monitoring, and benefit-risk assessment. The paper highlights expected gains in efficiency, data quality, and early risk identification, while also addressing challenges around explainability, regulatory acceptance, and data governance. Experts emphasize the importance of human oversight, hybrid AI models, and change management. The paper concludes that AI will become a core enabler of proactive, scalable drug safety operations.

Join for free to read